STAT+: Gossamer Lung Disease Drug Fails Late-Stage Study, but Company Will Still Seek FDA Approval

Why It Matters

The failure highlights the difficulty of delivering effective PAH therapies and may delay new treatment options, while Gossamer’s continued FDA pursuit could set a precedent for conditional approvals based on subgroup data.

Key Takeaways

• Phase 3 seralutinib missed primary efficacy endpoint.
• Walk distance improved 13 meters, not statistically significant.
• Cough affected 37% of patients; liver enzymes rose 13%.
• Company will still seek FDA approval based on subgroup signals.

Pulse Analysis

Pulmonary arterial hypertension (PAH) remains a lethal condition, with median survival under three years without effective therapy. Current treatments target vasodilation but do not reverse vascular remodeling, leaving a sizable unmet need for disease‑modifying agents. Gossamer Bio’s seralutinib is a selective inhibitor of the RET and KIT tyrosine kinases, pathways implicated in endothelial proliferation and inflammation. By aiming to curb the pathological remodeling of pulmonary arteries, the drug promised a novel mechanism that could complement existing prostacyclin, endothelin, and phosphodiesterase‑5 inhibitor regimens.

The Phase 3 trial enrolled patients with functional class II‑III PAH and measured six‑minute walk distance (6MWD) as the primary endpoint. Seralutinib‑treated participants walked an average of 13 meters farther than placebo, a directionally positive signal that fell short of statistical significance, suggesting limited power or heterogeneous response. Safety data revealed cough in 37 % of subjects and elevated liver enzymes in 13 %, adverse events consistent with the drug’s kinase inhibition profile.

These findings underscore the challenge of translating mechanistic rationale into robust clinical benefit across a broad PAH population. Despite the missed endpoint, Gossamer intends to file an FDA application, banking on post‑hoc analyses that identify subgroups—such as patients with higher baseline endothelin levels—who may derive meaningful improvement. The agency has increasingly entertained conditional approvals when a therapy shows promise in a defined niche, as seen with recent accelerated clearances in rare diseases. If granted, seralutinib could capture a segment of the $5 billion PAH market, but investors and clinicians will weigh the risk‑benefit profile carefully, especially given the safety signals.